UMB Bank N A MO trimmed its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 2.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 378,463 shares of the biopharmaceutical company’s stock after selling 8,762 shares during the period. UMB Bank N A MO’s holdings in Pfizer were worth $12,713,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer during the second quarter worth about $102,000. D. Scott Neal Inc. boosted its holdings in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the first quarter worth about $121,000. Cascade Investment Advisors Inc. boosted its holdings in shares of Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,200 shares during the period. Finally, Perennial Advisors LLC boosted its holdings in shares of Pfizer by 7.9% during the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 376 shares during the period. Institutional investors and hedge funds own 69.36% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) opened at $35.30 on Tuesday. Pfizer, Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market cap of $209,697.67, a P/E ratio of 14.07, a P/E/G ratio of 2.49 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company posted $0.61 earnings per share. analysts expect that Pfizer, Inc. will post 2.59 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 79.01%.

WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/14/umb-bank-n-a-mo-has-12-71-million-holdings-in-pfizer-inc-pfe.html.

PFE has been the subject of a number of research reports. Credit Suisse Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. BMO Capital Markets reissued a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research note on Wednesday, September 6th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target for the company. in a research note on Wednesday, September 13th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Tuesday, October 3rd. Finally, Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $38.48.

In other news, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 132,124 shares in the company, valued at approximately $4,492,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the transaction, the insider now owns 74,506 shares in the company, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. Insiders have sold a total of 374,621 shares of company stock worth $12,796,098 in the last quarter. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.